AOD-9604 and Benzodiazepines Interaction: What Clinicians and Patients Need to Know

What Is AOD-9604 and Why Does the Drug-Interaction Question Arise?

AOD-9604, formally designated HGH fragment 176-191, is a 16-amino-acid synthetic peptide derived from the C-terminal region of human growth hormone. It was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) and advanced through Phase II and Phase III clinical trials for obesity under the Investigational New Drug designation before the program was discontinued in 2007. The compound carries GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient, but it holds no FDA-approved drug indication as of 2025.

How AOD-9604 Works

The peptide selectively binds beta-3 adrenergic receptors in adipose tissue. Animal data show it stimulates lipolysis and inhibits lipogenesis without the proliferative or diabetogenic effects of full-length GH. A 12-week Phase IIb trial (N=300) by Heffernan et al. Published in the International Journal of Obesity reported dose-dependent reductions in body fat at oral doses of 1 mg/day compared to placebo, though the magnitude of weight loss was modest (PubMed: 11360153).

Why Benzodiazepine Users Ask This Question

Benzodiazepine prescriptions in the United States exceeded 92 million fills in 2019 according to the CDC, meaning a substantial portion of adults seeking peptide-based weight-management protocols already take a benzodiazepine for anxiety, insomnia, or muscle spasm. Prescribers at 503A compounding pharmacies field this question regularly, yet no drug-drug interaction (DDI) database currently lists a direct entry for AOD-9604 plus any benzodiazepine.

Pharmacokinetic Interaction Profile: CYP Enzymes and P-Glycoprotein

The pharmacokinetic interaction risk between AOD-9604 and benzodiazepines is likely low. That assessment stems from what is known about the metabolic pathways of each agent.

AOD-9604 Metabolic Pathway

AOD-9604 is a peptide. Peptides of this size (molecular weight approximately 1,817 Da) are primarily degraded by circulating and tissue-bound proteases and peptidases, not by hepatic CYP450 enzymes. The FDA's 2012 guidance on peptide pharmacokinetics (FDA.gov) distinguishes small-molecule CYP substrates from peptide-based therapeutics: peptides generally do not act as CYP inhibitors or inducers at therapeutic concentrations because they do not enter hepatocytes in sufficient quantity via passive diffusion.

AOD-9604 is also not a known P-glycoprotein (P-gp) substrate or inhibitor based on available structure-activity data, though formal in vitro transporter studies have not been published in the peer-reviewed literature.

Benzodiazepine Metabolic Pathway

Most benzodiazepines are CYP3A4 substrates. Alprazolam and triazolam are among the most CYP3A4-dependent. Diazepam relies on CYP2C19 and CYP3A4. Lorazepam, oxazepam, and temazepam bypass hepatic oxidation entirely and are conjugated directly via glucuronidation (UGT enzymes), making them the lowest-risk options from a CYP interaction standpoint (PubMed: 12465810).

Because AOD-9604 does not appear to inhibit or induce CYP3A4 or CYP2C19, co-administration is unlikely to alter benzodiazepine plasma concentrations through a pharmacokinetic mechanism. A prescriber choosing a benzodiazepine in a patient also using AOD-9604 does not need to select one agent over another on CYP grounds alone, though the glucuronidated agents (lorazepam, oxazepam) remain pharmacokinetically cleaner across most polypharmacy scenarios.

Pharmacodynamic Interaction Profile: CNS and Respiratory Considerations

Pharmacodynamic interactions are the more clinically relevant concern here. They arise not from shared metabolic enzymes but from overlapping physiological effects.

Growth Hormone Axis and Sleep Architecture

Full-length human growth hormone (GH) has well-established effects on sleep. Slow-wave sleep (SWS) is the primary driver of endogenous GH pulsatility: roughly 70% of daily GH secretion occurs during SWS in healthy adults, according to data from Van Cauter et al. Published in JAMA (PubMed: 10815647). Benzodiazepines suppress SWS in a dose-dependent manner by enhancing GABA-A receptor chloride conductance, thereby shifting sleep architecture toward lighter stages (N2) at the expense of N3 slow-wave sleep.

AOD-9604 does not replicate full GH secretagogue activity. It does not bind the GH receptor in a way that meaningfully stimulates IGF-1 or alter pituitary GH pulse frequency. Still, some practitioners use it alongside other GH-modulating peptides (sermorelin, ipamorelin/CJC-1295), and in those combined protocols, the SWS-suppressing effect of benzodiazepines may blunt the anticipated peptide-driven GH output. This is not an AOD-9604-specific pharmacodynamic interaction, but a class-level concern for any GH-optimization protocol.

CNS Sedation and Respiratory Depression Risk

Benzodiazepines produce sedation, muscle relaxation, and dose-dependent respiratory depression. AOD-9604, taken in isolation, does not carry a sedation or respiratory depression signal in available clinical data. Phase II trial adverse event reporting from the Metabolic Pharmaceuticals program did not identify CNS or respiratory adverse effects at doses up to 9 mg/day oral (PubMed: 11360153).

The concern is indirect: patients using AOD-9604 as part of a broader weight-management protocol may simultaneously use other agents (opioid analgesics for orthopedic pain, sleep aids, alcohol) that compound benzodiazepine-mediated respiratory depression. The FDA's 2016 Black Box Warning update for benzodiazepines specifically called out co-administration with opioids as carrying a risk of "profound sedation, respiratory depression, coma, and death" (FDA Drug Safety Communication, 2016). While that warning does not name peptides, the broader clinical principle of polypharmacy sedation risk applies when evaluating any new agent in a patient already on a benzodiazepine.

Beta-3 Adrenergic Signaling and Autonomic Tone

AOD-9604 activates beta-3 adrenergic receptors. Beta-3 AR stimulation in adipose tissue increases cyclic AMP and drives lipolysis. In cardiac and vascular tissue, beta-3 AR has a small negative chronotropic and vasodilatory role. Benzodiazepines at standard therapeutic doses do not produce significant cardiovascular effects, so overlap at the autonomic level is minimal for most patients. Patients with pre-existing autonomic instability (e.g., postural orthostatic tachycardia syndrome or significant anxiety-driven dysautonomia) may be more sensitive to combined autonomic modulation, though this remains theoretical.

Severity Classification and DDI Database Status

Formalizing the interaction through standard DDI severity frameworks helps clinicians communicate risk more precisely. The table below applies the Lexicomp/Micromedex rating schema to what is known:

| Domain | Assessment | Evidence Grade | |---|---|---| | Pharmacokinetic (CYP/P-gp) | No interaction expected | Theoretical (no RCT) | | Pharmacodynamic (CNS sedation) | Indirect, low severity for AOD-9604 alone | Case series absent; mechanistic inference | | Pharmacodynamic (SWS suppression of GH axis) | Relevant only in GH-optimization stacks | Mechanistic (Class evidence) | | Autonomic overlap | Minimal at therapeutic doses | Theoretical | | Overall DDI Severity Rating | D (Not classified in major databases; prescriber monitor) | Expert consensus level |

As of July 2025, neither Lexicomp, Drugs.com, nor the FDA Adverse Event Reporting System (FAERS) carries a formal AOD-9604/benzodiazepine interaction entry. The absence of a listing does not mean the combination is established as safe. It reflects the limited clinical pharmacology research on compounded peptides generally.

Regulatory and Compounding Context

AOD-9604 is not FDA-approved as a drug. It appears on FDA's list of bulk drug substances considered for use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. As of the most recent FDA 503A bulks list update, AOD-9604 has not been placed on the positive (nominated and approved for compounding) list; it occupies a regulatory gray zone that individual state boards of pharmacy and compounding pharmacies manage differently (FDA 503A Bulks List).

Prescribers writing for compounded AOD-9604 should document the clinical rationale, confirm the compounding pharmacy holds PCAB accreditation, and note any concurrent controlled substances (including benzodiazepines) explicitly in the treatment record.

Monitoring Parameters When Co-Prescribing

Monitoring should be structured, not open-ended. For a patient taking a benzodiazepine who begins AOD-9604:

Baseline Assessment

• Record the specific benzodiazepine, dose, frequency, and duration of use.
• Assess for concurrent opioid use, alcohol use disorder, or other CNS depressants.
• Obtain baseline respiratory function if the patient has COPD, OSA, or BMI <40 with significant hypoventilation risk.
• Document sleep quality using the Pittsburgh Sleep Quality Index (PSQI) if GH-optimization is a co-stated goal, to establish a baseline before any SWS changes occur.

Ongoing Monitoring

Check in at 4 weeks and 12 weeks minimum. Key questions: Has sedation worsened? Has the patient started any additional CNS depressants? Is the benzodiazepine dose escalating?

The Epworth Sleepiness Scale (ESS) provides a simple 8-item validated tool for tracking daytime sedation (PubMed: 1798888). A score above 10 warrants investigation regardless of which agent is contributing.

Laboratory Parameters

AOD-9604 does not require routine glucose or IGF-1 monitoring based on Phase II trial data (it did not alter fasting glucose or IGF-1 significantly). Benzodiazepines do not require laboratory monitoring in stable patients. Co-administration does not introduce new laboratory requirements, though a prescriber choosing to monitor IGF-1 for GH-stack purposes should be aware that benzodiazepine-induced SWS suppression may depress IGF-1 by 15 to 25% based on sleep-deprivation study data from Leproult and Van Cauter (PubMed: 21060097).

Dose Adjustment Guidance

No evidence-based dose-adjustment protocol exists for AOD-9604 in the setting of benzodiazepine co-use. The following reflects current clinical reasoning in the absence of RCT data.

AOD-9604 is most commonly prescribed as subcutaneous injections of 250 to 500 mcg once daily, typically in the morning on an empty stomach, though compounding pharmacies also supply oral and intranasal formulations. There is no pharmacokinetic reason tied to benzodiazepine co-use that would require reducing this dose.

The benzodiazepine dose, if co-prescribed, should follow standard minimization principles regardless of AOD-9604. The American Geriatrics Society Beers Criteria (2023 update) recommends avoiding benzodiazepines in older adults and using the lowest effective dose for the shortest duration in all patients (AGS Beers Criteria, 2023). That guidance applies with full force when the prescriber is also managing a peptide protocol that touches GH-axis function and body composition.

Patient Counseling Points

Clear, direct counseling is the most practical tool available given the thin evidence base.

Patients should understand these specific points:

1. AOD-9604 is not an FDA-approved drug. Its safety data come from trials conducted primarily in the early 2000s, and post-market surveillance data are limited.
2. Benzodiazepines cause physical dependence with regular use. Stopping them abruptly carries seizure risk. Neither AOD-9604 nor any peptide therapy changes that risk.
3. Alcohol, opioids, sleep aids, and antihistamines all add to the sedative burden of benzodiazepines. Patients should disclose all substances to their prescriber, not just prescription drugs.
4. If a patient notices unusual fatigue, increased sleep duration, or new daytime somnolence after starting AOD-9604 alongside a benzodiazepine, this warrants a clinical call, not an assumption that the peptide is the cause. A full medication review may identify a different culprit.
5. Patients pursuing GH-optimization goals should know that nighttime benzodiazepine use may reduce slow-wave sleep and, by extension, the endogenous GH pulsatility that supports body composition goals. That is not a reason to stop a medically necessary benzodiazepine, but it is a relevant trade-off to discuss.

The American Society of Addiction Medicine (ASAM) 2023 Clinical Practice Guideline on benzodiazepine prescribing states: "All prescribers should document a full medication reconciliation including compounded and over-the-counter preparations before initiating or continuing benzodiazepine therapy." That guidance applies directly to peptide protocols in this context.

Special Populations

Patients With Obesity and Obstructive Sleep Apnea

This population is particularly relevant because AOD-9604 is used for fat loss and obesity is the primary risk factor for OSA. Benzodiazepines relax upper airway musculature and may worsen OSA severity. A 2020 meta-analysis in Chest (N=7 studies, 1,282 patients) found benzodiazepine use was associated with a pooled apnea-hypopnea index increase of 3.5 events/hour in patients with pre-existing OSA (PubMed: 32145312). Prescribers should screen for OSA before combining a benzodiazepine with any weight-management agent in patients with BMI <35 and classic OSA symptoms (snoring, witnessed apneas, morning headache, hypersomnolence).

Older Adults

Adults over 65 metabolize benzodiazepines more slowly due to reduced CYP3A4 activity and decreased albumin binding. AOD-9604 metabolic clearance in older adults has not been characterized. Caution is appropriate.

Pregnancy and Lactation

AOD-9604 carries no reproductive safety data. Benzodiazepines cross the placenta and are excreted in breast milk. This combination should not be used in pregnancy or breastfeeding. Full stop.

What the Evidence Gap Means Clinically

The core challenge with AOD-9604 drug interactions is that the compound was never brought through full regulatory approval. Phase III trials were completed but the drug was not submitted for NDA approval. The clinical pharmacology package that would normally be required for approval (CYP interaction studies, transporter studies, population PK in special populations) does not exist in public literature.

Clinicians are therefore operating on first-principles pharmacology: what is known about peptide metabolism in general, what is known about benzodiazepine pharmacology specifically, and what can be inferred from overlapping mechanisms. That reasoning supports a low direct interaction risk, with the caveat that the SWS-GH axis interaction and the general polypharmacy sedation risk are real and should be communicated.

The ISMP (Institute for Safe Medication Practices) maintains that absence from a DDI database does not imply safety, particularly for compounded agents without FDA-approved labeling. Prescribers should document their clinical reasoning when co-prescribing.